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Abstract
Dendritic cells (DCs) are key players in the development of immunity. They can direct both the size
and the quality of an immune response and thus are attractive tools to mediate immunotherapy. DC
function has been thought to reflect the cells’ maturation, with immunosuppressive agents such as
IL-10 understood to retain DCs in an immature and tolerogenic state. Here we report that DC activated
in the presence of IL-10 do show functional and phenotypic maturation. Their activation is transient
and occurs earlier and more briefly than in cells matured with LPS alone. Despite initially equivalent
up-regulation of surface MHC and co-stimulation, the IL-10-treated DCs expressed little IL-12 and
failed to stimulate T cell proliferation both in vitro and in vivo. Interaction with IL-10-treated DCs
rendered antigen-specific T cells unresponsive to subsequent challenge and their injection reduced
the severity of experimental autoimmune disease. Our data suggest that IL-10 acts not by inhibiting
maturation but instead by controlling the kinetics and the quality of DC activation. This alternative
pathway of DC differentiation offers significant therapeutic promise.
Introduction
The central role of dendritic cells (DCs) in activating naive
T cells gives them a strategic position in the control of immu-
nity. They present to T cells both antigen and information
about the pathogen and tissue from which that antigen
came, and so they direct both the strength and the quality
of the T cell response (1). The outcome of DC action can be
as different as immunity and tolerance (2) and DCs are be-
ing investigated as therapeutic agents both to boost anti-
tumour responses (3, 4) and to alleviate autoimmunity or
graft rejection (5, 6). The distinct functions of DCs have often
been thought to reflect different stages of DC maturation,
with immunogenicity a feature of activated or ‘mature’ DCs
and tolerance induction restricted to resting, ‘immature’ cells
(7). The use of DCs to curtail unwanted immune responses
requires a stability of function, however, that is resistant to
any maturation stimuli encountered later, in vivo. We demon-
strate here that DCs can undergo a rapid and transient acti-
vation process and still elicit tolerance.
Classical understanding of DC biology pictures an imma-
ture cell stationed in the periphery, continuously sampling
its environment through phagocytosis and pinocytosis (8).
These cells migrate to the draining lymph node under
steady-state conditions, presenting their antigenic load in
the absence of adequate co-stimulation and thereby main-
taining self-tolerance (9). DC maturation occurs in the con-
text of infection or inflammation when signals from the host
or the invading microorganism trigger pattern recognition
receptors expressed by the DC and thus elicit a process in-
volving up-regulation of MHC and co-stimulatory molecules
and cytokine release that together transform the DC into
a powerful T cell stimulator (10, 11).
This definition of DC maturation has been muddied re-
cently by a growing appreciation of alternative patterns of
DC development (12). DCs can stimulate both Th1 and Th2
immunity (13) and yet the phenotype required to drive a Th2
response comprises little surface MHC or known co-stimula-
tion and thus shares few of the characteristics of classically
activated DCs (14–16). Lutz and Schuler (17) coined the term
‘semi-mature’ to describe a population of DCs that displayed
high levels of surface MHCII, CD80 and CD86 but did not
up-regulate cytokine production; despite their co-stimulatory
capacity, these cells elicited T cell tolerance in vivo (18). Sim-
ilar populations of ‘paralysed’ and ‘exhausted’ DCs have also
been reported (19, 20).
Several studies have used chemical or cytokine modifica-
tion of DC development in order to manipulate T cell
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responses (6). IL-10 is an immunosuppressive cytokine,
originally described as a product of a polarized Th2 clone
(21) and now known to be released by a variety of cells in-
cluding keratinocytes, B cells, macrophages and DCs (22,
23). Attempts to use IL-10 therapeutically have been difficult:
systemic administration in vivo has been shown to amelio-
rate experimental arthritis (24) but to aggravate symptoms
of experimental autoimmune encephalomyelitis (EAE) (25).
Concentrating its action onto appropriate cells and with rele-
vant timing appears critical for a suppressive outcome. The
impact of IL-10 on DCs is described as an inhibition of matu-
ration, preventing the up-regulation of activation markers
such as MHC class II and CD86, causing the DCs to interact
with T cells while still essentially immature (26). This gives
rise to an anergic or regulatory T cell response (26–28).
Tolerance induction by immature DCs can be broken by
concomitant DC activation, however (9). Here we investigate
the ability of mature DCs to elicit tolerance by driving DC ac-
tivation in the presence of IL-10. We reveal a transient and
accelerated activation that is accompanied by terminal dif-
ferentiation of the cells. Despite phenotypic equivalence to
classically activated DC controls, these DCs, in vivo, render
T cells profoundly unresponsive to subsequent challenge
and protect against experimental induction of EAE, a mouse
model of multiple sclerosis. They thus offer a significant and
stable therapeutic potential in the prevention of autoimmune
disease.
Methods
Mice
BALB/c, C57BL/6 and DO11.10 TCR transgenic [H-2Ad re-
stricted, ovalbumin peptide (OVA) 323–339 specific] (29)
mice were bred and maintained under specific pathogen-
free conditions in the animal facilities of the Faculties of
Medicine and Science and Engineering at the University of
Edinburgh. Mice were used at 6–12 weeks of age.
DC preparation
DCs were generated from bone marrow precursors under
the influence of granulocyte/macrophage colony-stimulating
factor (GM-CSF) using a protocol based on that of Inaba
et al. (30). Bone marrow was collected from murine femurs
and tibias and cell clusters dispersed by passage through
a 25-G needle. Red blood cells were removed using lysis
buffer (Sigma–Aldrich, Poole, UK). Cells were seeded into
24-well tissue culture plates at 3.75 3 105 cells per ml and
1 ml per well. The culture medium was RPMI 1640 (Sigma)
supplemented with 10% FCS (Labtech International, Lewes,
UK), 2 mM L-glutamine (Gibco BRL, Life Technologies, Pais-
ley, UK) and 50 U/ml penicillin plus 50 lg/ml streptomycin
(Gibco). GM-CSF was added in the form of 5% supernatant
from the transfected cell line X63-gmcsf (31). Cultures were
washed at day 3 and day 6 to remove non-adherent granulo-
cytes and lymphocytes. On day 7, loosely adherent DCs
were harvested by more vigorous washing, leaving firmly ad-
herent macrophages attached to the plate. DC preparations
were 85–90% pure (CD11c+, MHCII+) with the remainder of
cells predominantly Gr1+ granulocytes.
DC activation
Day 7 DCs were replated at 1 3 106 cells per ml and 1 ml
per well in fresh 24-well plates using culture medium with
GM-CSF. LPS (0.1 lg/ml; from Escherichia coli 055:B5,
Sigma) and recombinant mouse IL-10 (50 ng/ml; R&D sys-
tems, Abingdon, UK) were added as appropriate.
Flow cytometry
DCs were harvested at various times after activation, as
stated in the text, washed and stained for expression of
MHCII (I-Ad/I-Ed specific, FITC labelled, clone 2G9), CD11c
(PE labelled, HL3), CD80 (PE, 16-10A1) and CD86 (PE,
GL1), all from PharMingen (San Diego, CA, USA). The mem-
brane-impermeable dye ToPro3 (Molecular Probes, Leiden,
The Netherlands) was included for the final 5 min of staining.
Samples were analysed with a FACScalibur flow cytometer
and CellQuest software (Becton Dickinson, Mountain View,
CA, USA) using a live cell gate set by forward and side scat-
ter characteristics and ToPro3 exclusion. To measure cell
death, unstained cells were re-suspended in 1 lM ToPro3
immediately before acquisition. Analysis was then performed
on an ungated population.
Antigen uptake
DCs were harvested after activation, washed and 2 3 105
cells re-suspended in 50 ll PBS or FITC–dextran (2 mg/ml
in PBS; MW 70 000; Molecular Probes). Cells were incu-
bated at 37C or on ice for 45 min, flooded with ice-cold
PBS for 5 min, washed and re-suspended in 1% paraformal-
dehyde for analysis by flow cytometry.
RNA extraction and reverse transcriptase–PCR
Total RNA was isolated from 1 3 106 DCs using Trizol re-
agent (Gibco) and standard phenol–chloroform extraction.
cDNA was synthesized with the ExpandTM Reverse Tran-
scriptase kit (Roche Diagnostics, Lewes, UK). PCR used
Taq Supreme polymerase and buffers from Helena Bioscien-
ces (Sunderland, UK). Reactions were performed with an ini-
tial denaturation of 2 min at 94C followed by cycles of
denaturation for 30 s at 94C, annealing for 30 s and exten-
sion for 30 s at 68C. Primers and programmes were as
follows: IL-12p40, sense primer 5#-ATGGCCATGTGGGAGC-
TGGAGAAAG-3# and anti-sense primer 5#-GTGGAGCAG-
CAGATGTGAGTGGCT-3#, amplified product 255 bp,
annealing at 62C, 34 cycles; IL-12p35, 5#-GATCATGAAGA-
CATCACACGG-3# and 5#-AGAATGATCTGCTGATGGTTG-3#,
257 bp, annealing at 65C, 34 cycles and b-actin, 5#-GCAC-
CACACCTTCTACAATGAG-3# and 5#-GTCTAGAGCAACAT
AGCAC AGC-3#, 409 bp, annealing at 62C, 25 cycles.
Quantitative real-time reverse transcriptase–PCR
RNA was extracted as for reverse transcriptase (RT)–PCR
and treated with DNase1 (Gibco). cDNA was synthesized
using random hexamers and the TaqMan Reverse Transcrip-
tion kit (Perkin-Elmer Applied Biosystems, Foster City, CA,
USA). Real-time RT–PCR was performed as described (32).
Relative quantification was done on an ABI PRISM 7700
Sequence Detector (Perkin-Elmer) using pre-developed Taq-
Man reagents according to the manufacturer’s instructions.
1124 Transient activation of DC elicits tolerance
 by guest on A
ugust 23, 2013
http://intim
m
.oxfordjournals.org/
D
ow
nloaded from
 
Each reaction involved multiplex amplification of 18S rRNA to
account for differences in the quantity or quality of RNA pres-
ent. Thermal cycling conditions were 2 min at 50C and 10
min at 95C followed by 40 cycles of 2-step PCR consisting
of 15 s at 95C and 1 min at 60C. All samples were amplified
in triplicate. For each sample, the amount of target mRNA
was expressed as an n-fold difference relative to the amount
of target mRNA expressed by unstimulated DCs at 0 h.
IL-12 protein quantification
Supernatants were harvested from DC cultures 6 h after
stimulation and assessed for IL-12 p40 and p70 expression
by ELISA using paired mAb purchased from PharMingen. In-
tracellular cytokine staining was performed 6 h after stimula-
tion in the presence of GolgiStopTM (PharMingen) at
a dilution of 1:1500. Cells were then stained for CD11c be-
fore being fixed and permeabilized (BD Cytofix/CytopermTM
kit) and stained with a PE-conjugated antibody against IL-
12p40 (all from PharMingen). Samples were analysed by
flow cytometry using forward and side scatter characteristics
to gate on live cells.
T cell stimulation in vitro
DCs were harvested after activation, washed and pulsed
with graded doses of OVA (323-ISQAVHAAHAEINEAGR-
339; Albachem Ltd, Edinburgh, UK) for 90 min at 37C.
Pulsed DCs were washed and plated with CD4+ DO11.10
T cells at 1 3 104 DCs plus 1 3 105 T cells per 200 ll well.
Proliferation was measured as [3H]thymidine incorporation
during the last 16 h of a 3-day culture. CD4+ T cells were
purified from pooled spleen and lymph nodes by removing
MHCII- and CD8-positive contaminants with a MACS deple-
tion column (Miltenyi Biotec Ltd, Bisley, UK), and were rou-
tinely >80% CD3+ CD4+. Culture medium was as for DCs
but without GM-CSF. 2-Mercaptoethanol was added to
50 lM (BDH Merck, Poole, UK).
T cell stimulation in vivo
DO11.10 lymph node cells were injected intravenously into
BALB/c recipients using 5 3 106 cells per mouse. One day
later, mice received DCs that had been stimulated for 6 h
and pulsed with 50 lg/ml OVA (323–339), as above, using
5 3 105 DCs per mouse. Some mice were later rechallenged
in vivo using 25 lg OVA (323–339) emulsified in CFA con-
taining heat-killed Mycobacterium tuberculosis (Sigma)
injected subcutaneously into each hind leg. Responses were
assessed by harvesting the draining inguinal lymph nodes.
When a second cohort of DO11.10 cells were injected, these
were labelled with 5,6 carboxyfluoroscein diacetate succini-
midyl ester (CFSE) (Molecular Probes) at 10 nM for 8 min at
room temperature. In these experiments, one group received
200 lg alum-precipitated ovalbumin subcutaneously as
a cell-free alternative to DC immunization. Detection of
DO11.10 cells used the clonotypic antibody KJ1.26 (33), pu-
rified and biotinylated in-house.
Induction and assessment of EAE
C57BL/6 mice were immunized with 100 lg myelin oligoden-
drocyte glycoprotein (MOG35–55) peptide in a total volume of
100 ll CFA to induce EAE disease, injecting 50 ll subcuta-
neously into each hind leg. Mice also received 200 ng per-
tussis toxin (Health Protection Agency, Porton Down, UK)
intraperitoneally on the same day and 2 days later. Clinical
signs of EAE were assessed daily using a discrete scoring
system: 0, no signs; 1, flaccid tail; 2, impaired righting reflex
and/or impaired gait; 3, partial hind limb paralysis; 4, total
hind limb paralysis; 5, hind and fore leg paralysis; 6, mori-
bund or dead. When given, 5 3 105 DCs were delivered in-
travenously 21 days before disease induction.
Statistical analyses
Unpaired Student’s t-test was used to determine the statisti-
cal significance between two groups. Significant differences
in total disease burden of mice with EAE disease were cal-
culated using the Mann–Whitney U-test.
Results
DC activation is transient and occurs in the presence of IL-10
The cytokine signals received by DCs influence both their
own phenotype and that of the T cells they stimulate (34). To
obtain a population of DCs capable of suppressing pathologi-
cal T cell responses, we activated bone marrow-derived DCs
in the presence of the regulatory cytokine IL-10. LPS is an
archetypal DC stimulus and induced a clear wave of pheno-
typic activation, with expression of MHC and co-stimulatory
molecules increasing, peaking and falling again within a
24 h period (Fig. 1). The variation in expression was most
striking for CD86; surface levels of CD80 were comparatively
stable. DCs stimulated with LPS plus IL-10 achieved equiva-
lently strong up-regulation of CD86 but their peak expression
occurred earlier, around 3–6 h, and down-regulation was
much more advanced by 24 h (Fig. 1). Throughout the time
course, the expression of the DC marker CD11c was stable
and similar for both populations of cells (not shown). Thus,
the regulatory function of IL-10 appears not to be a simple
inhibition of maturation; its influence is kinetic.
IL-10-treated DCs are fully differentiated
To confirm the activation status of DCs stimulated in the pres-
ence of IL-10, we assessed their ability to internalize a fluo-
rescent antigen. The switch from antigen uptake to antigen
presentation is a hallmark of classical DC activation (8, 35),
allowing antigen uptake to be used as a measure of immatu-
rity. Unstimulated, immature DC exposed to FITC–dextran
actively internalized the antigen and became brightly fluo-
rescent (Fig. 2A). Cells that had been matured in LPS for
24 h acquired less antigen: in a typical experiment, the
mean fluorescence of this population fell from 89 to 39 units
(Fig. 2A). DCs stimulated with LPS and IL-10 also showed
reduced antigen uptake, their fluorescence matching that of
LPS-treated DCs rather than unstimulated cells. The fully dif-
ferentiated nature of the IL-10-treated DCs was further dem-
onstrated by their limited lifespan in culture (Fig. 2B). The
final consequence of DC activation is death (36), and while
unstimulated cells lived longer than either population given
LPS, IL-10-treated DCs again behaved as mature cells: their
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death rate matched that of cells in LPS alone, suggesting that
IL-10 accelerates DCs through activation and on into death.
Activation is cytokine deficient
To determine whether IL-10 affected the quality of DC activa-
tion as well as its kinetics, we examined IL-12 production by
RT–PCR. Both p40 and p35 genes were strongly induced by
LPS stimulation, with or without IL-10 (Fig. 3A). The response
was short-lived, with down-regulation of both genes appar-
ent by 14 h post-stimulation. Although the kinetics were af-
fected, with p40 expression peaking earlier in the presence
of IL-10 (Fig. 3A), the dominant effect was one of scale. This
was reinforced when the samples were quantified by real-
time RT–PCR (Fig. 3B). DCs activated in the presence of
IL-10 displayed a brief, early up-regulation of IL-12 p40. Ex-
pression was maximal 2 h after stimulation, 2000-fold above
the pre-stimulation background and had returned to baseline
by 6 h. This response was dwarfed by that seen with LPS
alone, with peak expression then 10-fold higher. The p35
subunit showed a similar pattern: although transcription was
Fig. 1. DC phenotype after stimulation. DCs were harvested at day 7 of culture and stimulated with LPS or LPS plus IL-10. Samples were taken
for analysis by flow cytometry at various times afterwards. Data shown is gated on CD11c+ cells and open peaks represent isotype controls. The
data are representative of four separate experiments.
Fig. 2. Terminal differentiation of IL-10-treated DCs. (A) DCs were replated with or without LPS and IL-10 for 24 h before being washed and
pulsed with FITC–dextran (2 mg/ml). Internalization was assessed by flow cytometry. Open peaks indicate background uptake when incubated
on ice; filled peaks show specific uptake at 37C. Numbers give the mean fluorescent intensity for all cells at 37C. (B) DCs were stimulated with
or without LPS and IL-10 and stained with the membrane impermeant dye ToPro3 at various times afterwards. The graph shows percentage cell
death as a function of time. Both sets of data are representative of at least three independent experiments.
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induced in the presence of IL-10, the effect was stronger in
its absence. Notably, the decrease in IL-12 expression seen
when IL-10 was included in the DC stimulation was not ac-
companied by any detectable increase in IL-10 production;
the exogenous IL-10 in fact acted to suppress the IL-10 eli-
cited by LPS alone (Fig. 3C).
To demonstrate that the transcriptional inhibition of p40
and p35 caused by IL-10 translated into a reduction in IL-12
protein expression, the cytokine content of DC cultures was
assayed by ELISA 6 h after stimulation (Fig. 4A). The inhibi-
tion of LPS-elicited IL-12 in DCs activated in the presence
of IL-10 was stark. Intracellular cytokine staining for the IL-
12 p40 subunit confirmed that the impact of IL-10 was to re-
duce both the number of DCs producing IL-12 and the
mean quantity of IL-12 generated per cell (Fig. 4B).
T cell stimulation is impaired
The defining feature of DC activation is their capacity to
stimulate naive T cells. To assess this, we pulsed DCs with
the 323–339 peptide of ovalbumin and cultured them with
CD4+ cells taken from DO11.10 mice, engineered to express
an OVA (323–339)-reactive transgenic TCR (29). When the
DCs were used 24 h after stimulation, the presence of IL-10
during DC activation suppressed subsequent T cell prolifera-
tion to a level not equal to but consistently below that elicited
by the unstimulated control DCs (Fig. 5A). This was in keep-
ing with the limited expression of MHC and co-stimulatory
molecules by IL-10-treated DCs at this time point (Fig. 1).
Importantly, even at 6 h post-stimulation and despite equiva-
lent surface levels of MHCII, CD80 and CD86, IL-10-treated
DCs still did not prime T cells as effectively as their LPS-ma-
tured counterparts (Fig. 5B). This effect was as striking in
vivo as in vitro: mice given a cohort of TCR transgenic, OVA
(323–339)-reactive CD4+ cells showed a significantly smaller
expansion of antigen-specific cells following administration
of peptide-pulsed, IL-10-treated DCs harvested 6 h after
stimulation than those injected with DCs activated in LPS
alone (Fig. 5C).
Tolerance induction
The reduced T cell response seen after in vivo stimulation of
DO11.10 cells by IL-10-treated DCs (Fig. 5C) could repre-
sent either a deficit in T cell priming or an active induction
of non-responsiveness. To distinguish the two possibilities,
recipients of transferred OVA (323–339)-specific CD4+
T cells were then immunized with OVA (323–339)-pulsed
DCs and later rechallenged with the same peptide in CFA.
When the draining lymph nodes were cultured ex vivo with
antigen, those from mice first injected with LPS-stimulated
DCs showed robust proliferation (Fig. 6). In contrast, when
the initial immunization was with IL-10-treated DCs, prolifera-
tion after secondary challenge was completely absent.
To test whether the lack of secondary response after ad-
ministration of DCs activated in the presence of IL-10 (Fig. 6)
Fig. 3. Cytokine expression in IL-10-treated DCs. DCs were stimulated with LPS and IL-10 and samples taken for RNA extraction at various times
afterwards. (A) Expression of the two IL-12 subunits assessed by RT–PCR using b-actin for comparison. H2O, water blank. (B and C) Quantitative
real-time RT–PCR. Y-axis scale indicates an n-fold increase above expression at 0 h. Data are representative of three independent experiments.
Transient activation of DC elicits tolerance 1127
 by guest on A
ugust 23, 2013
http://intim
m
.oxfordjournals.org/
D
ow
nloaded from
 
Fig. 4. IL-12 production by DCs. (A) Expression of IL-12 protein measured in DC supernatants was assessed 6 h after stimulation by ELISA.
Dashed line indicates limit of detection. (B) Intracellular cytokine staining for IL-12p40 was performed after 6 h stimulation in the presence of
monensin. Numbers give the percentage of live CD11c+ cells positive for IL-12p40 and the y-axis mean fluorescent intensity of these cells.
Quadrant gates were drawn using isotype control staining in each case. Data are representative of (A) two and (B) three independent
experiments.
Fig. 5. IL-10-treated DCs stimulate a limited Tcell response. DCs were harvested, replated with or without LPS and IL-10 for either (A) 24 h or (B)
6 h, pulsed with OVA and co-cultured with DO11.10 T cells. Proliferation was measured during the last 16 h of a 72-h culture. Data are shown as
the mean of triplicate cultures 6 standard error of mean, and is representative of four independent experiments. (C) Mice received an adoptive
transfer of DO11.10 LNC 24 h before being immunized with DCs-given medium alone (unstimulated), LPS or LPS plus IL-10 for 6 h before being
pulsed with OVA. Mice were sacrificed 5 days after immunization and the percentage of DO11.10 cells in CD4+ splenocytes was measured by
flow cytometry. Each point represents an individual mouse and the graph is representative of seven independent experiments, each using 4–5
mice per group. *P = 0.011 and **P = 0.004.
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was caused by the induction of a suppressive or regulatory
cell population, we injected a second cohort of naive TCR
transgenic T cells into mice that had earlier received both
DO11.10 Tcells and DC immunization (Fig. 7A). While the pro-
liferation of the second delivery of TCR transgenic T cells in
response to CFA challenge was diminished in mice previously
administered IL-10-treated DCs (Fig. 7B), this reduction was
no more marked than in mice originally injected with either
control DCs or indeed peptide in alum (Fig. 7C). The ability
of any immunization to inhibit the proliferative capacity of the
second cohort of transgenic cells may then reflect competi-
tion for access to antigen or antigen presenting cell following
strong expansion of the original population of antigen-specific
cells (37) and so, using this model, we failed to detect any
activity of suppressive cells in vivo after administration of IL-
10-treated DCs.
DCs activated in the presence of IL-10 suppress central
nervous system autoimmune disease
To assess the therapeutic potential of the profound hypores-
ponsiveness induced in antigen-specific T cells by DCs acti-
vated in the presence of IL-10, we used an EAE model in
which paralysis was initiated by immunization of C57BL/6
mice with the p35–55 peptide of MOG (38). When MOG35–55-
pulsed DCs were administered to mice before induction of
EAE, and despite their phenotypic equivalence to LPS-acti-
vated cells, only the IL-10-treated DCs significantly reduced
the severity of disease (Fig. 8). Interestingly, this effect was
partially independent of peptide antigen: IL-10-treated DCs
that were not loaded with MOG35–55 also inhibited disease,
although to a lesser extent than their peptide-pulsed equiva-
lents. Thus, activating DCs in the presence of IL-10 drives
a tolerogenic phenotype capable of limiting central nervous
system autoimmune disease.
Discussion
DCs can direct both the size and character of an immune re-
sponse and so are attractive candidates as immunotherapy
in a range of clinical disorders (39). The immunogenic and
tolerogenic functions of DCs have been understood to repre-
sent distinct stages of DC maturation (9, 40). Here we stimu-
late DCs in the presence of the regulatory cytokine IL-10 and
demonstrate the ability of a fully differentiated DC phenotype
to curtail T cell responses in vivo. We reveal a kinetic and
qualitative influence of IL-10 on the process of DC activation,
suggesting that a simple functional separation of immature
and mature DCs may not be sufficient to describe the biol-
ogy of these cells, and offering significant potential for a sta-
ble DC-mediated therapy against autoimmune disease,
allergy and transplant rejection.
IL-10 is one of a number of factors reported to modulate DC
function by holding the DC in immaturity (41–43). Other exam-
ples include apoptotic cells (35, 44), malaria-infected eryth-
rocytes (45) and steroidal anti-inflammatories (46), so the
mechanism of regulation is relevant to immunity, tolerance,
infection and therapy. We have shown that DCs activated in
the presence of IL-10 do respond to an LPS stimulus, down-
regulating antigen uptake and increasing expression of
MHC and CD80/86, but that this activation is transient. The
apparent immature phenotype reported by others describing
DCs 48 h or more after addition of IL-10 (26, 47–49) is there-
fore consistent with the observations presented here, even if
the kinetics of DC activation in human monocyte-
derived DCs are slower than in murine bone marrow equiva-
lents (50). The distinction of our data is that the DCs here
are phenotypically activated when they meet T cells, and yet
the T cell outcome remains tolerance. This regulatory function
could indicate the presence of tolerogenic molecules on the
surface of IL-10-treated DCs (51, 52), although our analysis
Fig. 6. Secondary challenge of Tcells in vivo. Mice received an adoptive transfer of DO11.10 LNC prior to immunization with DCs-given medium
alone, LPS or LPS plus IL-10 for 6 h and pulsed with OVA. Seven days later, all mice were challenged with OVA in CFA. Positive controls
(rechallenge only) received an adoptive transfer of DO11.10 cells 24 h before immunization with the same OVA in CFA as the experimental mice.
Negative controls (No Ag) were given LPS DCs without antigen at immunization and PBS in CFA at rechallenge. Draining LNs were collected 10
days after rechallenge, pooled within groups and plated for ex vivo culture with graded doses of OVA peptide. Proliferation was measured by
[3H]thymidine incorporation and data are shown as the mean of triplicate wells 6 standard error of mean. The graph is representative of two
independent experiments, each using 4–6 mice per group.
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revealed no significant expression of PDL-1 or RANK (not
shown). A kinetic explanation is also possible. Our data show
that the high levels of MHC and CD80/86 on our IL-10-
treated DCs are not maintained. Their decline is rapid, with
down-regulation almost complete within 24 h in the presence
of IL-10. The surface of mature DCs is considered relatively
stable: the half-life of MHCII has been measured at over
100 h (53). This implies that the reduction in marker expres-
sion is an active process, not a passive loss. If the interaction
between DCs and responding T cells is normally a lengthy
Fig. 7. Competitive suppression of antigen-specific Tcells in vivo. (A) Experimental outline: Mice received an adoptive transfer of DO11.10 LNC
prior to immunization with DCs given medium alone, LPS or LPS plus IL-10 for 6 h and pulsed with OVA. Twenty-four hours before all mice were
later challenged with OVA in CFA, a second cohort of DO11.10 cells was administered, these labelled with CFSE. Proliferation of this group of T
cells was measured by CFSE fluorescence and flow cytometry. (B) Example plots showing clear division of CFSE-labelled cells. (C) Data are
shown as the percentage of the labelled cohort of DO11.10 cells that had undergone 4 or more cell divisions when analysed on day 10. Each
point represents an individual mouse and the graph is representative of three independent experiments, each using 3–4 mice per group. While
the proliferation seen in all three groups immunized with DCs was significantly reduced below that in mice receiving only the OVA–CFA
rechallenge (***P = 0.0002), there was a significant difference neither between them nor between the IL-10-treated DC group and control mice in
which alum-precipitated antigen was used to drive strong proliferation of the original DO11.10 cells (OVA–alum).
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conversation (54), then the premature down-regulation of
key DC molecules may be sufficient to limit T cell prolifera-
tion. Their activation would literally be aborted (55).
A kinetic mechanism of tolerance induction, in which DCs
stimulated in the presence of IL-10 undergo early activation,
rapid down-regulation and subsequent death is supported
by the recorded ability of IL-10 to promote DC apoptosis
(56–58). Our data demonstrate that the action of IL-10 is not
mediated solely by apoptotic removal of mature, immuno-
genic cells, since the phenotypically immature DCs present
24 h after addition of LPS and IL-10 show reduced antigen
acquisition quite distinct from that of unstimulated cells. In-
stead, IL-10 appears to influence DC function by dictating
the timing of progression into terminal maturation. The apo-
ptotic death that marks the end point of this maturation pro-
cess may offer an explanation for the degree of inhibition of
autoimmune disease mediated by IL-10-treated DCs not
loaded with specific peptide antigen: DCs in the recipient
mouse could capture both dying, IL-10-treated DCs and the
MOG35–55 peptide later delivered in CFA. The expected out-
come would be MOG35–55-specific tolerance (59). That
peptide-loaded DCs retain a more potent influence on dis-
ease progression than equivalents without antigen suggests
that specific contact between an IL-10-treated DC and
responding T cells permits additional, kinetic mechanisms of
tolerance induction.
If DC regulation was purely kinetic, the Tcell outcome would
be dictated by the stage of differentiation that the DC had
reached as it arrived in the lymph node. If it met a specific
T cell at the height of activation, then strong immunity would
result; if it was past its peak, the consequent immune re-
sponse would be different, perhaps even tolerant. This is an
extension of Lanzavecchia and colleagues’ description of DC
exhaustion (20, 60). Simplistically, it predicts that the same
activation should occur in the presence and absence of IL-
10 with the only difference being one of timing. This is indeed
what happens in terms of surface phenotype, but analysis of
the IL-12 expression of the two DC populations also revealed
qualitative differences. Bioactive IL-12 is a p70 heterodimer.
In DCs regulation appears to focus on the p35 subunit (61,
62) and an excess of p40 can form inhibitory homodimers
(63). Our data show that the presence of IL-10 during DC
stimulation inhibits the release of both p40 and p70 proteins.
Temporal regulation and alternative activation may thus be
complementary. The kinetic profiles of the individual co-stim-
ulatory molecules differ: the variation in expression is more
pronounced for CD86 than CD80, for example. The balance
of co-stimulatory signals provided by DCs will consequently
change over time, influencing the T cell outcome (52, 64, 65).
Interestingly, even at the peak of their activation, the IL-10-
treated DCs here did not themselves produce IL-10. Several
reports have associated IL-10 secretion by DCs with either
Th2 (66–68) or Tr1 induction (69, 70). DC-derived cytokines
may contribute to T cell activation as well as polarization
(71). Two descriptions of DCs that appeared phenotypically
activated but secreted little cytokine both recorded a conse-
quent suppression of T cell responses (18, 72). Lutz and
Schuler (17) termed such DCs semi-mature, a description
that befits their poor performance in both cytokine release
and T cell stimulation, and the concept that the process of
DC maturation can be separated into distinct stages has
persisted (73–75). Our data add a kinetic perspective and
thus further challenge the association between DC matura-
tion and a functional conversion from tolerogenic to immuno-
genic cells. In support, Rea et al. (76) have demonstrated
that suppression of DC function by the steroid dexametha-
sone was concomitant with maturation and Albert et al. (77)
reported that both cross-priming and cross-tolerance require
mature DCs. Reis e Sousa (12) has recently argued that the
present model or semantics of DC maturation may need to
be revised. Certainly, the impact of activating DCs in the
presence of IL-10 currently appears paradoxical, with inter-
pretations of resulting immaturity (42, 43) alongside evidence
of positive gene induction and biological effects (78, 79).
Activation of IL-10-treated DCs may have a physiological
importance. Preliminary data suggest that, while DCs given
LPS for 24 h or more are resistant to the effect of IL-10, at
6 h post-stimulation, they remain responsive (not shown).
Fig. 8. IL-10-treated DCs protect from autoimmunity. DCs were
stimulated with LPS or LPS plus IL-10 for 6 h and pulsed with MOG35–55
peptide. These DCs were injected into mice 21 days before
immunization with MOG35–55 in CFA to induce EAE disease. Data are
shown as the mean disease score for the 5 mice in each group and the
graphs are representative of two independent experiments. Mice
receiving IL-10 DCs + MOG showed a significantly lower disease
burden than that of the PBS controls (P < 0.0001).
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B cells have been shown to react to IL-12 by releasing IL-10,
which implies that activated B cells in secondary lymphoid
tissues could down-regulate Th1 responses by dampening
the stimulatory capacity of DCs (80). Since activation of B
cells is a relatively late event in an immune response, any
such B cell regulation would have to act on mature or matur-
ing DCs as they arrive from the periphery as part of a sus-
tained influx. This fits more easily with a kinetic or qualitative
regulation of DC activation than with a strict inhibition of mat-
uration, which would require the presence of IL-10 in the pe-
ripheral tissues. This type of regulation could explain recent
data from an EAE model in which an IL-10 deficiency was
restricted to B cells (38) and exacerbated disease was
shown to correlate with increased levels of IFNc. Importantly,
the early response of these animals was similar to that of
controls, but they then failed to recover: the regulation oc-
curred late in the immune response. This may reflect the ac-
tion of B cell-released IL-10 on DCs.
In infection, an uncoupling of DC maturation and strong
immunity could be detrimental: pathogens able to subvert
the process could activate DCs to create an immunosup-
pressive environment that favours microbial replication rather
than host survival (81). As tools to counter unwanted or ex-
cessive immune responses, however, the potential of acti-
vated and tolerogenic DCs is significant. The use of
immature DCs to drive tolerance in vivo is tempered by the
need to preserve that immaturity (82, 83) even in the face of
ongoing infection or inflammation. Indeed, a recent report
has demonstrated that the tumour necrosis factor a-treated
DCs which originated the term semi-mature (18) remain
open to stimulation and convert into classically activated, im-
munogenic DCs upon subcutaneous injection (84). The fully
differentiated, tolerogenic phenotype that we describe
implies a functional stability (9, 85) and hence reduced risk
of unwanted exacerbation of the T cell response.
In summary, IL-10 has a powerful influence on DC func-
tion. We show that this is achieved not by preventing DC
maturation, but by directing a rapid and transient activation
that leaves the DC fully differentiated and able both to elicit
T cell tolerance in vivo and protect against autoimmune dis-
ease. We suggest that these DCs have significant therapeu-
tic potential.
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